Tirzepatide injections at full potency activate both GLP-1 and GIP pathways, creating dual appetite suppression and metabolic benefits that drive sustained weight loss
Eden gives you access to licensed providers who can tailor treatment and follow-up based on your evolving needs
The most common complaints are gastrointestinalnausea, cramps, or diarrheawhich usually resolve when the dose is reduced or stopped
V., Lieberman M., Sampalis F., and Sampalis J
Tirzepatide has demonstrated up to 22.5% weight loss in phase 3 trials [38], while other agents like cagrisema (GLP-1/amylin RA) and retatrutide (GLP-1/GIP/glucagon RA) show even greater efficacy in early-phase studies [13]
Studies show this combination improves blood sugar, promotes weight loss, and has low hypoglycemia risk when used appropriately